PCVX - Vaxcyte Inc

PCVX - Vaxcyte Inc

https://vaxcyte.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Vaxcyte ( PCVX ) Q2 Loss Widens 11%

Motley Fool • 1 month, 1 week ago • score: 0.27

Vaxcyte ( NASDAQ:PCVX ) , a biotechnology company specializing in next-generation vaccines, reported its second quarter 2025 results on August 6, 2025. The company reported a GAAP net loss per share of $ ( 1.22 ) , missing the consensus estimate of $ ( 1.16 ) .

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - Vaxcyte ( NASDAQ:PCVX )

Benzinga • 4 months, 2 weeks ago • score: 0.23

SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc.

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Business Insider • 4 months, 2 weeks ago • score: 0.21

SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran ...

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

GlobeNewswire • 4 months, 2 weeks ago • score: 0.14

SAN CARLOS, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Vaxcyte, Inc. ( Nasdaq: PCVX ) , a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran ...

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

Zacks Commentary • 5 months ago • score: 0.12

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.

52W High

$121.06

52W Low

$27.66

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.04

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-14.43

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.40

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.66%

Institutions (25–75% balanced)

114.93%

Shares Outstanding

129,823,000

Float

116,968,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-75,000,000

EPS (TTM)

-4.11

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.22%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.3202

Previous

-0.5245

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025